LEP and metabolic dysfunction-associated steatotic liver disease: Since there are no drugs that target leptin, we believe that, based on the current state of research, leptin can reduce the incidence of NAFLD without duplicating the mechanism of action of other existing drugs for NAFLD and can be used as a complement to existing treatment regimens.